Wall Street brokerages expect Cytokinetics (NASDAQ:CYTK) to announce sales of $5.57 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Cytokinetics’ earnings, with the highest sales estimate coming in at $6.10 million and the lowest estimate coming in at $5.03 million. Cytokinetics reported sales of $3.05 million during the same quarter last year, which would suggest a positive year over year growth rate of 82.6%. The firm is expected to issue its next earnings report on Wednesday, August 1st.
On average, analysts expect that Cytokinetics will report full year sales of $23.60 million for the current financial year, with estimates ranging from $22.27 million to $25.58 million. For the next financial year, analysts anticipate that the firm will report sales of $135.02 million per share, with estimates ranging from $24.80 million to $245.24 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cytokinetics.
Get Cytokinetics alerts:Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). The business had revenue of $5.27 million during the quarter, compared to analyst estimates of $5.50 million. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 99.50%.
A number of equities research analysts recently issued reports on the stock. BidaskClub raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a report on Saturday, April 28th. Piper Jaffray Companies dropped their price objective on shares of Cytokinetics to $13.00 and set an “overweight” rating for the company in a report on Monday. Cantor Fitzgerald reissued a “hold” rating and issued a $10.00 price objective on shares of Cytokinetics in a report on Sunday. ValuEngine raised shares of Cytokinetics from a “sell” rating to a “hold” rating in a report on Friday, April 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Cytokinetics in a report on Friday, April 27th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $15.56.
Shares of Cytokinetics traded up $0.10, reaching $8.35, during mid-day trading on Friday, according to MarketBeat Ratings. The company’s stock had a trading volume of 647,061 shares, compared to its average volume of 359,235. The stock has a market capitalization of $536.56 million, a price-to-earnings ratio of -3.19 and a beta of 1.17. The company has a quick ratio of 7.07, a current ratio of 7.07 and a debt-to-equity ratio of 0.32. Cytokinetics has a 1-year low of $6.75 and a 1-year high of $15.95.
In other Cytokinetics news, EVP Fady Ibraham Malik sold 3,000 shares of the stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $8.95, for a total transaction of $26,850.00. Following the completion of the transaction, the executive vice president now owns 96,067 shares of the company’s stock, valued at $859,799.65. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert I. Blum sold 4,000 shares of the stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $7.52, for a total transaction of $30,080.00. Following the transaction, the chief executive officer now directly owns 182,701 shares of the company’s stock, valued at approximately $1,373,911.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,000 shares of company stock valued at $123,570. 5.10% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in CYTK. DRW Securities LLC purchased a new position in Cytokinetics during the first quarter worth about $101,000. Virtu Financial LLC purchased a new position in Cytokinetics during the fourth quarter worth about $112,000. Teacher Retirement System of Texas purchased a new position in Cytokinetics during the fourth quarter worth about $113,000. Ellington Management Group LLC purchased a new position in Cytokinetics during the fourth quarter worth about $128,000. Finally, Granite Investment Advisors LLC purchased a new position in Cytokinetics during the fourth quarter worth about $151,000. 68.01% of the stock is owned by institutional investors.
Cytokinetics Company Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.
Get a free copy of the Zacks research report on Cytokinetics (CYTK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Aperio Group LLC increased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 49.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 19,270 shares of the biopharmaceutical company’s stock after buying an additional 6,377 shares during the period. Aperio Group LLC’s holdings in Lexicon Pharmaceuticals were worth $165,000 as of its most recent SEC filing.